Advertisement
U.S. markets open in 3 hours 30 minutes
  • S&P Futures

    5,302.50
    -5.75 (-0.11%)
     
  • Dow Futures

    40,131.00
    -13.00 (-0.03%)
     
  • Nasdaq Futures

    18,470.00
    -33.75 (-0.18%)
     
  • Russell 2000 Futures

    2,134.20
    -4.20 (-0.20%)
     
  • Crude Oil

    81.84
    +0.49 (+0.60%)
     
  • Gold

    2,217.80
    +5.10 (+0.23%)
     
  • Silver

    24.56
    -0.20 (-0.80%)
     
  • EUR/USD

    1.0778
    -0.0051 (-0.47%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    13.02
    +0.24 (+1.88%)
     
  • GBP/USD

    1.2593
    -0.0045 (-0.36%)
     
  • USD/JPY

    151.4440
    +0.1980 (+0.13%)
     
  • Bitcoin USD

    70,541.68
    +516.24 (+0.74%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,969.87
    +37.89 (+0.48%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Today’s Research Reports on Stocks to Watch: Mylan and Nutanix

NEW YORK, NY / ACCESSWIRE / December 4, 2017 / Shares of Mylan headed higher after revealing an FDA approval for a generic version of Heparin Sodium and after rumors surfaced that the company could be in talks with Amazon. Shares of Nutanix also soared to near IPO highs after strong earnings and the company announcing that it would be a software-only business.

RDI Initiates Coverage on:

Mylan N.V.
http://www.rdinvesting.com/report/?ticker=MYL

Nutanix, Inc.
http://www.rdinvesting.com/report/?ticker=NTNX

Mylan N.V. shares closed up 4.35% on Friday on nearly 7.8 million shares traded. It was a day of gains for the biotech stock after it was announced that the FDA has approved the company's generic blood thinner. Mylan had submitted an application to the FDA for a generic version of Heparin Sodium which was approved for four different doses. The company has said that U.S. sales of Heparin Sodium at these injectable doses were $185 million for the year ended October 31st. Company president Rajiv Mailk commented, "We are very proud of today's FDA approval of Heparin Sodium Injection as this approval adds yet another highly complex and difficult-to-manufacture product to our portfolio." Shares soared to a 5 week high after the approval on Friday. It was also revealed that the company could be in discussion with Amazon but it is unclear over what.

Access RDI's Mylan N.V. Research Report at:
http://www.rdinvesting.com/report/?ticker=MYL

Nutanix, Inc. shares closed up 9.94% on nearly 21 million shares traded on Friday. The stock hit a brand new high of $38.28 during intra-day trading on account of new software focus that has traders excited. Friday's high was a level the stock hadn't seen since going public last September. More than half of the analysts that are covering Nutanix have lifted their price targets after it was revealed that the company is going to be a software-only business. It was the best day of gains since May of 2016 and the highest close for the stock since October of 2016. The company's CFO Duston Williams said that Nutanix "will be focusing even more intently on selling software going forward." The company's latest quarterly report also had traders cheering. For the first quarter, Nutanix reported revenue of $276 million and a non-GAAP loss of $0.16 per share. Analysts had been expecting revenue of $267 million and a loss of $0.26. In the last three months, shares of Nutanix have rallied over 63%.

Access RDI's Nutanix, Inc. Research Report at:
http://www.rdinvesting.com/report/?ticker=NTNX

Our Actionable Research on Mylan N.V. (NASDAQ: MYL) and Nutanix, Inc. (NASDAQ: NTNX) be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

Advertisement